Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | JAK2 | O60674 | 2/20 | 0.33 |
| ▸ | JAK1 | P23458 | 2/20 | 0.33 |
| ▸ | TYK2 | P29597 | 2/20 | 0.33 |
| ▸ | JAK3 | P52333 | 2/20 | 0.33 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.32 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25423241 | 0.84 | CYP1A2 (0.41) | CYP1A2CYP3A4CYP2C9CYP2C19MAOB | |
| SCHEMBL1298778 | 0.80 | LMNA (0.38) | LMNAMAP3K14CYP2C9KDM4ENPC1 | |
| SCHEMBL13088423 | 0.79 | LMNA (0.40) | LMNAMAP3K14CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL15956851 | 0.77 | CYP2C9 (0.37) | LMNAMAP3K14CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL2060019 | 0.76 | LMNA (0.38) | LMNAMAP3K14CYP3A4CYP2C19KDM4E | |
| SCHEMBL1396053 | 0.73 | LMNA (0.38) | LMNAMAP3K14CYP3A4CYP2C19KDM4E | |
| SCHEMBL15956594 | 0.72 | LMNA (0.42) | LMNAMAP3K14KDM4ENPC1RAB9A | |
| SCHEMBL1854385 | 0.72 | KDM4E (0.37) | LMNAMAP3K14KDM4ENPC1RAB9A | |
| SCHEMBL17174644 | 0.72 | CYP2C19 (0.46) | LMNAMAP3K14CYP2C19KDM4ENPC1 | |
| SCHEMBL15527837 | 0.72 | GAA (0.44) | LMNACYP3A4CYP2C9CYP2C19KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4463457-B1 | PYRROLO[1,2-B]-2-PYRIDAZINONE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | SUVEN LIFE SCIENCES LTD (IN) | 2026-02-04 | — | — | EP | disclosed |
| US-12275746-B2 | Pyrrolo[1,2-b]-2-pyridazinone compounds as 5-HT4 receptor agonists | SUVEN LIFE SCIENCES LIMITED (IN) | 2025-04-15 | — | — | US | disclosed |
| US-20250019386-A1 | PYRROLO[1,2-b]-2-PYRIDAZINONE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | SUVEN LIFE SCIENCES LIMITED (IN) | 2025-01-16 | — | — | US | disclosed |
| EP-4463457-A1 | PYRROLO[1,2-/b]-2-PYRIDAZINONE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | Suven Life Sciences Limited (IN) | 2024-11-20 | — | — | EP | disclosed |
| WO-2023135508-A1 | PYRROLO[1,2-b]-2-PYRIDAZINONE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | SUVEN LIFE SCIENCES LIMITED (IN) | 2023-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12275746-B2 | Pyrrolo[1,2-b]-2-pyridazinone compounds as 5-HT4 receptor agonists | HTR4, HTR5A, HTR1B | LMNA 4071/4885MAP3K14 1752/4885CYP1A2 215/4885 |
| US-20250019386-A1 | PYRROLO[1,2-b]-2-PYRIDAZINONE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | HTR4, HTR5A, HTR1B | LMNA 4071/4885MAP3K14 1752/4885CYP1A2 215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.